# Radiotherapy With Chemotherapy as Neoadjuvant Therapy of Resectable and Borderline Resectable Pancreas Cancer

> **NCT01333332** · PHASE2 · UNKNOWN · sponsor: **University of Virginia** · enrollment: 35 (estimated)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Capecitabine
- **RADIATION:** Standard Dose Acclerated Fraction Radiotherapy

## Key facts

- **NCT ID:** NCT01333332
- **Lead sponsor:** University of Virginia
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-08
- **Primary completion:** 2012-08
- **Final completion:** —
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2011-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01333332

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01333332, "Radiotherapy With Chemotherapy as Neoadjuvant Therapy of Resectable and Borderline Resectable Pancreas Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01333332. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*